Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Lara Meisner is Chief Legal Officer at Bicara Therapeutics. OQRO lists 4 transactions filed with the SEC under this name, the latest on Sep 17, 2025, each linked to the official Form 4.
Chief Legal Officer
Disclosures on record
4
Companies involved
1
Bicara TherapeuticsBCAX
4 disclosures · Mar 2025 – Sep 2025 · 4 sold
Sep 15, 2025Sold~$182Kdisclosed Sep 17
DetailsOfficial recordJun 16, 2025Sold~$165Kdisclosed Jun 18
DetailsOfficial recordMar 14, 2025Sold~$616Kdisclosed Mar 18
DetailsOfficial recordMar 14, 2025Sold~$406Kdisclosed Mar 18
DetailsOfficial recordLara Meisner has no open-market purchase on record since 2022 across 2 companies. Sales in 3 of the 5 years since 2022.
Lara Meisner reported 0 open-market purchases and 18 sales since 2022; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2025 | — | $1.37M4×4 trades |
| 2023 | — | $1.37M7×7 trades |
| 2022 | — | $1.17M7×7 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Lara Meisner has no open-market purchase on record since 2022 across 2 companies. Sales in 3 of the 5 years since 2022.
In SEC filings since 2022: no open-market purchase is on record; the latest open-market sale is from 2025.
2 companies: Bicara Therapeutics (BCAX, 2025), Viridian Therapeutics, Inc. (VRDN, 2022–2023).
Lara Meisner reported 0 open-market purchases and 14 sales here, 2022 to 2023.
Lara Meisner reported 0 open-market purchases and 4 sales here, 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
